2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2672

Ultrasonography in the Diagnosis of Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2607

Ultrasound Detection of Calcinosis and Correlation with Ulnar Artery Occlusion in Patients with Systemic Sclerosis

Systemic Sclerosis & Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2644

Ultrasound to Monitor Treatment Response in Large Vessel Giant Cell Arteritis

Vasculitis – Non-ANCA-Associated & Related Disorders Poster III: Giant Cell Arteritis

9:00AM-11:00AM: Abstract Number: 2083

Understanding Knee Function and Symptom Management in Individuals with Risk Factors for Knee Osteoarthritis

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases – ARP

9:00AM-11:00AM: Abstract Number: 2037

Understanding Langerhans Cell ADAM17 Levels in Systemic Lupus Erythematosus: Potential Contributor to Photosensitivity

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2251

Understanding Vulnerabilities in Diagnosis and Care of Childhood and Adult-Onset Lupus: A Qualitative Study

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2479

Unmet Treatment Needs in Patients with Psoriatic Arthritis

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2570

Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2629

Urinary Inflammatory Cell Analysis Reflects the Renal Histopathology in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2637

Urine Complement Ba Levels During Flares of Renal Disease in Patients with ANCA-Associated Vasculitis

Vasculitis – ANCA-Associated Poster I

9:00AM-11:00AM: Abstract Number: 2059

Usage of Predicting Out-of-Office Blood Pressure Calculator in Hispanic Patients with Rheumatic Diseases

Epidemiology & Public Health Poster III: OA, Gout, & Other Diseases

9:00AM-11:00AM: Abstract Number: 2394

Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2462

Use of Complementary and Alternative Medicine (CAM) in a Psoriatic Arthritis Cohort

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 2412

Use of Minimal Important Difference (MID) in Randomized Clinical Trials of Pain in Osteoarthritis

Research Methodology Poster – ARP

9:00AM-11:00AM: Abstract Number: 2410

Using External Data to Estimate Omitted Variables in Observational Data: A Plasmode Simulation Study Investigating the Relationship Between Osteoarthritis and Cardiovascular Diseases to Compare Alternative Approaches in Imputing the Body Mass Index Variable

Research Methodology Poster – ARP

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].